Capstone Holding Corp. lowers convertible note conversion price to $1.00
Lawrence Erik Kurzius, a director at Elanco Animal Health Inc (NYSE:ELAN), recently purchased shares worth $211,000, according to a recent SEC filing. The transactions took place on March 7 and March 11, 2025, with Kurzius acquiring a total of 20,000 shares of common stock. The purchase prices ranged from $10.20 to $10.90 per share. The timing appears strategic, as the stock trades near its 52-week low with a market capitalization of $5 billion. According to InvestingPro analysis, the company’s shares are currently undervalued.
Following these acquisitions, Kurzius now holds 111,459 shares directly. This move reflects continued confidence in Elanco Animal Health, a company specializing in pharmaceutical preparations within the life sciences sector. The company maintains a strong financial position with a current ratio of 2.44, indicating healthy liquidity. InvestingPro subscribers have access to 7 additional key insights about ELAN’s valuation and growth prospects, along with comprehensive research reports covering 1,400+ US stocks.
In other recent news, Elanco Animal Health reported its fourth-quarter 2024 earnings, highlighting a mixed performance. The company missed the earnings per share (EPS) forecast by $0.01, reporting an EPS of $0.14, while revenue surpassed expectations, reaching $1.02 billion against the anticipated $1.01 billion. Despite the EPS shortfall, Elanco’s guidance for 2025 remains optimistic, with expected organic constant currency revenue growth of 4% to 6%. Stifel analysts maintained a Buy rating for Elanco but lowered the stock price target from $16.00 to $15.00, citing challenges such as currency exchange impacts on EBITDA forecasts and leverage targets. However, they noted positive aspects like the U.S. adoption rate of Zenrelia and promising revenue guidance for 2025. Elanco’s strategic initiatives, including product innovation and debt reduction, also continue to be a focus. The company expects adjusted EBITDA growth between 1% and 5% for 2025, with innovation revenue projected to reach between $640 million and $720 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.